depemokimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
depemokimab

GtoPdb Ligand ID: 14305

Synonyms: depemokimab-ulaa | Exdensur® | GSK-3511294 | GSK3511294

depemokimab is an approved drug

Compound class: Antibody

Comment: Depemokimab (GSK-3511294) is a humanized IgG1κ monoclonal; antibody that targets interleukin 5 (IL-5). It binds to the same epitope as, but with higher affinity mepolizumab [4].

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Depemokimab was engineered as an ultra-long-acting (twice-yearly administration) anti-IL-5 therapeutic, principally for the treatment of severe eosinophilic asthma [2-4].

Immunopharmacology Comments

Depemokimab was engineered as an ultra-long-acting (twice-yearly administration) anti-IL-5 therapeutic, principally for the treatment of severe eosinophilic asthma [2-4].